“`html
France Grapples with rising Obesity Rates Amidst Anti-Obesity Drug Concerns
Table of Contents
France faces a growing obesity crisis,with nearly half teh population overweight. New anti-obesity drugs like Wegovy and mounjaro offer hope but raise concerns about misuse and side effects."/>
France is confronting a significant public health challenge as obesity rates surge, impacting nearly half of its adult population. The rise in overweight and obese individuals has spurred the introduction of anti-obesity medications like Wegovy and Mounjaro, legally available as late 2024. Though, concerns are mounting over the misuse of these drugs by individuals seeking to lose only a few pounds, leading to potential health risks and illegal online sales.
Obesity Crisis in France: A Growing Concern
A study published in The Lancet projects that by 2050, 60% of the world’s population will be classified as obese or overweight The Lancet Study. France is particularly affected, with 47% of adults overweight and 17% obese. Alarmingly, obesity rates have quadrupled among 18-24 year olds in the last two decades, according to French Health Insurance data French Health Insurance. This crisis contributes to approximately 140,000 deaths per year due to cardiovascular diseases.
In response, the French government plans to launch an “obesity plan” in September, which may include the reimbursement of Wegovy and Mounjaro, anti-obesity drugs already legally marketed in France.
Did You Know? Cardiovascular diseases are the leading cause of death globally,accounting for an estimated 17.9 million deaths each year,according to the World Health Institution WHO.
The promise and Peril of Anti-Obesity Drugs
Wegovy and Mounjaro contain the semaglutide molecule, which acts on intestinal hormones to stimulate insulin secretion and create a feeling of fullness. Laetitia Lévy, a patient prescribed this treatment, reported losing 15 pounds through weekly injections. she noted improvements in her breathing and mobility, enhancing her overall quality of life. These drugs, however, come at a cost of approximately 300 euros per month and are currently not reimbursed by Social Security.
The High Authority for Health (HAS) has limited prescriptions to adults with a body mass index (BMI) of 35 kg/m² or greater, indicating severe obesity. It is estimated that between 1 and 2.1 million patients in France meet this criterion. The average weight loss achieved with these medications is around 17%.
Pro Tip: Calculate your BMI using a reliable online calculator to understand your weight status and potential health risks.
Misuse and Illegal Sales: A Growing Concern
Despite regulations, there is evidence of widespread misuse of these drugs for cosmetic weight loss. Social media platforms feature influencers promoting the drugs, while illegal online marketplaces offer them without prescriptions at reduced prices. This unregulated access poses significant health risks to individuals who may not meet the medical criteria for these medications.
